Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Waldron Private Wealth LLC

Waldron Private Wealth LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 359 shares of the biopharmaceutical company’s stock after acquiring an additional 61 shares during the quarter. Waldron Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $315,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Markel Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock valued at $56,083,000 after buying an additional 1,000 shares during the period. Cibc World Market Inc. increased its stake in Regeneron Pharmaceuticals by 1.4% during the first quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after purchasing an additional 86 shares during the period. Blair William & Co. IL increased its stake in Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares during the period. Sequoia Financial Advisors LLC increased its stake in Regeneron Pharmaceuticals by 23.1% during the first quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 93 shares during the period. Finally, Baird Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 100.9% during the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock worth $25,513,000 after purchasing an additional 18,345 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $898.56 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The business has a fifty day moving average of $956.81 and a two-hundred day moving average of $889.95. The company has a market cap of $98.63 billion, a P/E ratio of 25.86, a price-to-earnings-growth ratio of 2.64 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $10.96 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,729 shares of company stock worth $13,124,641. 8.83% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Truist Financial reiterated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $970.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.